vs

Side-by-side financial comparison of Amalgamated Financial Corp. (AMAL) and MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI). Click either name above to swap in a different company.

Amalgamated Financial Corp. is the larger business by last-quarter revenue ($85.2M vs $49.9M, roughly 1.7× MARAVAI LIFESCIENCES HOLDINGS, INC.). On growth, Amalgamated Financial Corp. posted the faster year-over-year revenue change (9.4% vs -11.8%). Amalgamated Financial Corp. produced more free cash flow last quarter ($134.4M vs $-24.9M). Over the past eight quarters, Amalgamated Financial Corp.'s revenue compounded faster (4.3% CAGR vs -11.9%).

CI Financial is a Canadian investment management company based in Toronto, Ontario. It offers investment management and wealth management services targeted to high net worth retail investors, as well as brokerage and trading services to portfolio managers and institutional investors.

Maravai LifeSciences Holdings is a global life sciences firm developing critical reagents, diagnostic products, and tech solutions to support biopharma research, drug development, clinical diagnostics, and cell/gene therapy manufacturing. It serves biotech, pharma, research bodies and labs worldwide across three core segments.

AMAL vs MRVI — Head-to-Head

Bigger by revenue
AMAL
AMAL
1.7× larger
AMAL
$85.2M
$49.9M
MRVI
Growing faster (revenue YoY)
AMAL
AMAL
+21.2% gap
AMAL
9.4%
-11.8%
MRVI
More free cash flow
AMAL
AMAL
$159.3M more FCF
AMAL
$134.4M
$-24.9M
MRVI
Faster 2-yr revenue CAGR
AMAL
AMAL
Annualised
AMAL
4.3%
-11.9%
MRVI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AMAL
AMAL
MRVI
MRVI
Revenue
$85.2M
$49.9M
Net Profit
$-35.7M
Gross Margin
25.8%
Operating Margin
39.0%
-117.9%
Net Margin
-71.6%
Revenue YoY
9.4%
-11.8%
Net Profit YoY
-37.7%
EPS (diluted)
$0.88
$-0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMAL
AMAL
MRVI
MRVI
Q4 25
$85.2M
$49.9M
Q3 25
$85.6M
$41.6M
Q2 25
$80.9M
$47.4M
Q1 25
$77.0M
$46.9M
Q4 24
$77.9M
$56.6M
Q3 24
$81.0M
$69.0M
Q2 24
$78.5M
$69.4M
Q1 24
$78.3M
$64.2M
Net Profit
AMAL
AMAL
MRVI
MRVI
Q4 25
$-35.7M
Q3 25
$26.8M
$-25.6M
Q2 25
$26.0M
$-39.6M
Q1 25
$25.0M
$-29.9M
Q4 24
$-25.9M
Q3 24
$27.9M
$-97.1M
Q2 24
$26.8M
$-9.8M
Q1 24
$27.2M
$-12.1M
Gross Margin
AMAL
AMAL
MRVI
MRVI
Q4 25
25.8%
Q3 25
13.6%
Q2 25
16.4%
Q1 25
16.5%
Q4 24
34.3%
Q3 24
46.7%
Q2 24
44.4%
Q1 24
40.3%
Operating Margin
AMAL
AMAL
MRVI
MRVI
Q4 25
39.0%
-117.9%
Q3 25
42.9%
-98.6%
Q2 25
43.8%
-139.8%
Q1 25
45.1%
-104.9%
Q4 24
42.4%
-66.7%
Q3 24
47.2%
-239.9%
Q2 24
45.6%
-19.4%
Q1 24
49.2%
-29.4%
Net Margin
AMAL
AMAL
MRVI
MRVI
Q4 25
-71.6%
Q3 25
31.3%
-61.4%
Q2 25
32.1%
-83.5%
Q1 25
32.5%
-63.9%
Q4 24
-45.8%
Q3 24
34.5%
-140.6%
Q2 24
34.1%
-14.1%
Q1 24
34.8%
-18.8%
EPS (diluted)
AMAL
AMAL
MRVI
MRVI
Q4 25
$0.88
$-0.24
Q3 25
$0.88
$-0.18
Q2 25
$0.84
$-0.27
Q1 25
$0.81
$-0.21
Q4 24
$0.78
$-0.21
Q3 24
$0.90
$-0.68
Q2 24
$0.87
$-0.07
Q1 24
$0.89
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMAL
AMAL
MRVI
MRVI
Cash + ST InvestmentsLiquidity on hand
$291.2M
$216.9M
Total DebtLower is stronger
$291.8M
Stockholders' EquityBook value
$794.5M
$212.4M
Total Assets
$8.9B
$770.6M
Debt / EquityLower = less leverage
1.37×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMAL
AMAL
MRVI
MRVI
Q4 25
$291.2M
$216.9M
Q3 25
$115.5M
$243.6M
Q2 25
$171.1M
$269.9M
Q1 25
$65.7M
$285.1M
Q4 24
$60.7M
$322.4M
Q3 24
$149.2M
$578.2M
Q2 24
$58.0M
$573.2M
Q1 24
$155.2M
$561.7M
Total Debt
AMAL
AMAL
MRVI
MRVI
Q4 25
$291.8M
Q3 25
$292.8M
Q2 25
$293.9M
Q1 25
$294.9M
Q4 24
$295.9M
Q3 24
$521.7M
Q2 24
$522.5M
Q1 24
$523.3M
Stockholders' Equity
AMAL
AMAL
MRVI
MRVI
Q4 25
$794.5M
$212.4M
Q3 25
$775.6M
$245.4M
Q2 25
$754.0M
$265.9M
Q1 25
$736.0M
$300.6M
Q4 24
$707.7M
$325.3M
Q3 24
$698.2M
$344.9M
Q2 24
$646.0M
$434.7M
Q1 24
$616.8M
$410.7M
Total Assets
AMAL
AMAL
MRVI
MRVI
Q4 25
$8.9B
$770.6M
Q3 25
$8.7B
$849.2M
Q2 25
$8.6B
$897.0M
Q1 25
$8.3B
$959.8M
Q4 24
$8.3B
$1.0B
Q3 24
$8.4B
$1.3B
Q2 24
$8.3B
$1.4B
Q1 24
$8.1B
$1.4B
Debt / Equity
AMAL
AMAL
MRVI
MRVI
Q4 25
1.37×
Q3 25
1.19×
Q2 25
1.11×
Q1 25
0.98×
Q4 24
0.91×
Q3 24
1.51×
Q2 24
1.20×
Q1 24
1.27×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMAL
AMAL
MRVI
MRVI
Operating Cash FlowLast quarter
$135.8M
$-22.8M
Free Cash FlowOCF − Capex
$134.4M
$-24.9M
FCF MarginFCF / Revenue
157.8%
-49.9%
Capex IntensityCapex / Revenue
1.6%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$229.4M
$-70.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMAL
AMAL
MRVI
MRVI
Q4 25
$135.8M
$-22.8M
Q3 25
$39.5M
$-15.2M
Q2 25
$24.9M
$-10.3M
Q1 25
$34.2M
$-9.4M
Q4 24
$124.1M
$-14.6M
Q3 24
$35.8M
$13.1M
Q2 24
$28.0M
$17.4M
Q1 24
$31.3M
$-8.5M
Free Cash Flow
AMAL
AMAL
MRVI
MRVI
Q4 25
$134.4M
$-24.9M
Q3 25
$38.3M
$-18.1M
Q2 25
$24.2M
$-13.1M
Q1 25
$32.5M
$-14.6M
Q4 24
$122.3M
$-20.5M
Q3 24
$35.2M
$4.5M
Q2 24
$27.8M
$7.9M
Q1 24
$31.1M
$-14.1M
FCF Margin
AMAL
AMAL
MRVI
MRVI
Q4 25
157.8%
-49.9%
Q3 25
44.7%
-43.4%
Q2 25
29.9%
-27.7%
Q1 25
42.2%
-31.2%
Q4 24
157.0%
-36.2%
Q3 24
43.4%
6.6%
Q2 24
35.4%
11.4%
Q1 24
39.7%
-22.0%
Capex Intensity
AMAL
AMAL
MRVI
MRVI
Q4 25
1.6%
4.2%
Q3 25
1.4%
7.0%
Q2 25
0.9%
6.1%
Q1 25
2.3%
11.2%
Q4 24
2.3%
10.3%
Q3 24
0.7%
12.4%
Q2 24
0.3%
13.8%
Q1 24
0.3%
8.8%
Cash Conversion
AMAL
AMAL
MRVI
MRVI
Q4 25
Q3 25
1.47×
Q2 25
0.96×
Q1 25
1.37×
Q4 24
Q3 24
1.28×
Q2 24
1.05×
Q1 24
1.15×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMAL
AMAL

Segment breakdown not available.

MRVI
MRVI

Cygnus Segment$27.2M54%
Other$18.4M37%
Shipping And Handling$4.3M9%

Related Comparisons